Introduction
Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease. For many patients, steady deterioration ultimately culminates in reduced life expectancy. 1 The phosphodiesterase type 5 inhibitor sildenafil is approved for the treatment of PAH in adults.
Adult patients with PAH who received sildenafil monotherapy had significantly improved exercise capacity (measured by 6-minute walk distance [6MWD]) and hemodynamic parameters compared with placebo-treated patients in a randomized, double-blind clinical study (SUPER-1). Patients who completed STARTS-1 were eligible to enroll in the STARTS-2 extension study. For the results presented, all patients had the potential for 3 years of treatment with sildenafil.
Methods

Study Design
The design of the STARTS-1 study has been previously reported. 3 Children ( In STARTS-2, patients who received sildenafil in STARTS-1 were maintained on their randomized sildenafil dose (low, medium, or high dose). Placebo-treated STARTS-1 patients were randomized (stratified by weight) to 1 of the 3 sildenafil dose groups at the beginning of STARTS-2. Patients in the >20-45 kg and >45 kg weight group strata were randomized in a 1:1:1 ratio; patients 8-20 kg were randomized to medium-or high-dose sildenafil in a 1:2 ratio.
To prevent treatment unblinding in STARTS-1, the double-blind was maintained until the Throughout STARTS-2, both upward (for disease progression or lack of improvement) and downward (for intolerability) dose titrations of sildenafil were permitted, per investigator judgment; titration was blinded until August 2008. A maximum of 2 uptitrations and 1 downtitration were allowed during the study. Doses received after dose titrations were equivalent to those in other dose groups (eg, a low-dose group patient who uptitrated once received a sildenafil dose equivalent to that of a medium-dose group patient in the same weight group).
Dummy uptitrations were used (during the blinded portion of the study) for patients who were already receiving the highest dose within their weight group (ie, a high-dose group patient received only dummy uptitrations if the investigator wanted to increase the dose; medium-dose by the dose resulting from up-or down-titration. Alterations in dosing were also made in accordance with changes in weight; however, dose changes in response to changed weight resulted in a patient receiving the relevant dose for that weight within the same dose group.
Patients discontinued study treatment if additional PAH-specific therapy (ie, prostacyclin analogues, endothelin receptor antagonists) was deemed appropriate by the investigator.
Information regarding therapy received following discontinuation (eg, no therapy, commercial sildenafil, others) was not specifically collected. Adverse events (AEs) were recorded throughout STARTS-1 and -2, and are presented for the entire STARTS program. Survival status was recorded every 3 months. All patients enrolled in STARTS-1, regardless of whether they enrolled in STARTS-2 or discontinued from either STARTS-1 or -2, were followed for survival whenever possible (contactable and consented).
STARTS-1 took place at 32 centers in 16 countries. Local institutional review boards approved the protocol; written informed consent was obtained from each child's guardian; child assent was obtained when applicable. 
Statistical Analysis
Comparison of Treatment Groups
Kaplan-Meier estimates of survival were assessed 1) from baseline of the STARTS-1 study and 2) from the start of sildenafil treatment, to account for the 16-week delay in receipt of sildenafil for patients randomized to placebo in STARTS-1. Thus, for the second analysis, survival was assessed from STARTS-2 baseline in placebo-treated STARTS-1 patients who were rerandomized to sildenafil treatment groups in STARTS-2; for all other patients, survival was assessed from STARTS-1 baseline. Analyses were conducted for patients overall, and because of differences in allocation ratios, by weight strata ( 20 vs >20 kg). Analyses of survival were by randomized dose group; hence, upward and downward titrations were not taken into account in analyses. As noted, patients who discontinued the study were followed for survival whenever possible; patients were censored on the last date they were known to be alive. The number of patients known to be alive at different times was also summarized, and is the most conservative estimate of survival because it assumes that patients who were lost to follow-up had died.
Cox proportional hazard models, stratified by baseline weight ( 20 vs >20 kg), were used to make comparisons between treatment groups. Hazard ratios are presented with 95% confidence intervals. The p-value for the comparison of the treatment groups was calculated by using a stratified log-rank test. Alternative models were used to explore the influence of individual covariates on the treatment comparisons.
Exploratory Analyses to Investigate the Relationship Between Baseline Parameters and
Survival
The association between baseline parameters and survival was investigated using Cox proportional hazard models. Parameters evaluated in univariate analyses included PAH etiology, andomized dose group; hence, upward and downward titrations were not taken in in into to o a acc ccou ou ount nt nt i in n analyses. As noted, patients who discontinued the study were followed for survival whenever po oss ss ssib ib ible le le; ; pa pa pati ti tie ents ts s w w were censored on the last date e t t the he ey were known n n to be be e a a ali l ve. The number of pati i ien e ts known wn t t to o be be a a ali ive ve ve a a at t t di d diff ffer er ere en ent t ti im mes s w w was a al als so s s su um umma ma mari rize ze ed d, , a and nd nd is s th th he e mo most st st c c con on nse e er rv rva at ativ v ve es sti ti tima ma mate te t o of f f su su surv rvi iv iva al al b bec ecau au a se se i i it t as as assu su sum me mes s th th that at at pa a ati ti t en en nt ts s w w who ho o w w wer r re e e lo lo ost st t t t Cox proportional hazard models were also used to examine all 2-and 3-parameter combinations of factors (ignoring the treatment effect) to select the model(s) that best predicted mortality (based on chi-square statistic). The influence of these variables on the treatment comparisons was assessed by including them in the stratified Cox proportional hazard models.
Results
Of the 234 patients who were randomized and treated in STARTS-1, 6 patients discontinued STARTS-1 and an additional 8 did not enter STARTS-2; of these 14, 5 patients receiving placebo in STARTS-1 did not enter STARTS-2 and therefore never received sildenafil treatment.
Baseline characteristics of STARTS-1 patients have been previously reported. 3 STARTS-1 patients were predominantly female (62%). PAH was idiopathic or heritable (IPAH/HPAH) in 33% and associated with congenital heart defect (PAH-CHD) in 67%; mean time from diagnosis was 1.7 (range, 0-12.4) years and 6.0 (range, 0-17) years, respectively.
Disease was WHO functional class I or II in 83% of patients. Mean (± SD) PVRI was 15±10 and combinations of factors (ignoring the treatment effect) to select the model(s) that at t b bes e e t predicted mortality (based on chi-square statistic). The influence of these variables on the r rea ea atm tm tme en ent t t co co com m mpar ar aris is iso ons was assessed by includin n ng g g th h hem in the stra a ati t t fied ed d C C Cox proportional hazard m mod de dels. (88%), and 55/60 (92%) of patients in sildenafil low-, medium-, and high-dose groups and the placebo group, respectively. Dose uptitrations, which resulted in doses received being equivalent to those in other dose groups (see Methods), occurred most frequently in the low-dose group (Table 1) . Therapy received (if any) following discontinuation, including possible treatment with commercial sildenafil, was not specifically collected.
Deaths
Thirty-seven patients were known to have died before August 4, 2011 (Supplementary Table   1 ). One death occurred within the first year of study treatment (STARTS-1 baseline), 9 during the second year, 9 during the third year, and 18 after the third year. Of these 37 deaths, 26 died while on treatment and 11 died after withdrawal from treatment (defined as >7 days after last study dose; median [range], 287 days after last dose). Twenty-eight (76%) patients who died had IPAH/HPAH (n=19 female) versus 33% of patients overall; 5 (n=4 female) had surgically repaired and 4 (n=3 female) had non-repaired PAH-CHD. Baseline disease was functional class III/IV in 38% of the deaths (vs 15% overall). The majority of patients who died had worse-than-median STARTS-1 baseline hemodynamic values: 68%, 76%, 68%, and 73% for mPAP, PVRI, CI, and RAP, respectively ( Table 2) ; 78% (25 of 32 patients with available baseline data) had NT-proBNP greater than the median value.
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T Thir ir rt ty-seven p pat at tie ient nts s we we ere re e k k kno no nown wn n t The percentage of deaths in the overall cohort was higher for the high-dose sildenafil group (22%) than for the medium-and low-dose groups (13.5% and 9%, respectively; Table 3 ).
This imbalance in the number of deaths in the high-dose group was apparent in children in the middle-weight category (>20-45 kg), but not in children 8-20 or >45 kg. Posthoc analyses performed using different definitions of "actual" dose (ie, other than randomized dose) also showed a higher percentage of deaths in patients receiving high-dose sildenafil (Supplementary Table 2 ). Most deaths were assessed by the investigator as associated with disease progression.
No deaths were considered by the investigator to be causally related to study treatment.
Survival From STARTS-1 Baseline
Kaplan-Meier estimated 3-year survival from STARTS-1 baseline for patients randomized to low-, medium-, and high-dose sildenafil and placebo in STARTS-1, as well as the most conservative estimates of 3-year survival (assuming that all patients lost to follow-up had died), are shown in Tables 4 and 5 . Estimates were lowest in the high-dose group.
Survival From Initiation of Sildenafil Treatment
Kaplan-Meier estimated 3-year survival from the start of sildenafil treatment (ie, baseline for patients who received placebo in STARTS-1 was the beginning of STARTS-2) for patients randomized to low-, medium-, and high-dose sildenafil in STARTS-2, as well as conservative estimates of 3-year survival, are shown in Table 4 and Figure 1A . Estimates were lowest in the high-dose group. Greater separation between doses was observed in patients weighing >20 kg, becoming evident after year 2 ( Figures 1B and 1C ).
Children with PAH-CHD had better Kaplan-Meier estimated 3-year survival than children with IPAH/HPAH (Table 4) .
Cox Regression Analysis
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The hazard ratios from the Cox regression analyses indicated a greater risk of death with higher compared with lower sildenafil doses or placebo (ie, a 16-week delay in sildenafil treatment; Table 6 ).
Risk of Mortality
Eleven baseline characteristics were significantly (P<0.05) associated with mortality in univariate analyses. For individual variables, the difference in patients' baseline values associated with a 10% reduction in mortality was derived (ie, for each "difference" value given, divergence in patients' baseline values by that amount confers [or is associated with] a 10% lower risk of death; Table 7 ).
The combination of variables with the highest predictive ability included etiology, PVRI, and RAP, when assessed from STARTS-1 baseline. This set of variables was also one of the best combinations when assessing survival from the start of sildenafil, although several different sets of variables (including different 3-variable combinations of etiology, PVR, RAP, WHO functional class, systolic PAP, diastolic PAP and systemic pulse pressure) performed similarly.
To assess the influence of baseline variables on the treatment comparisons, the impact of different combinations on the hazard ratios was investigated (see below).
Additional Analyses of Deaths
Additional analyses were undertaken to attempt to understand the higher incidence of deaths observed in the high-dose sildenafil group versus low-and medium-dose groups. Primary analyses were performed by randomized (not received) sildenafil dose. Using randomized doses is less prone to bias but is insensitive to imbalances between groups in dose alterations during the study; additionally, no information was collected on PAH-specific therapy received (if any) after patients discontinued the study. Examination of patterns of titration revealed that majority of
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To assess the e in in infl flue ue uenc nc nce e e of of ba ba base seli li line ne n v v var r ria ia i bl bl b es es e o o on n n th th the e tr tr t ea ea atm tm tmen en ent t t co co comp mp par ar aris is ison on ons, s, s, t the he he i i imp mp mpac ac a t of uptitrations occurred in patients randomized to low-dose sildenafil (51%; versus 15% and 13% in medium-and high-dose groups, respectively; Table 1 ). Imbalances were observed between treatment groups in baseline variables identified as prognostic of survival (Table 2) . Adjustment for some 3-variable combinations identified as being prognostic reduced hazard ratios (covariates: etiology, baseline RAP, and baseline PVRI) for mortality for high-and medium-dose sildenafil versus placebo and high versus lower sildenafil doses (Table 6 ), while others did not (ex: covariates of etiology, baseline RAP and systolic PAP).
Adverse Events
Most patients reported 1 AE during STARTS-1 and -2. The most frequently reported AEs were upper respiratory tract infection, headache, and vomiting; Supplementary convulsion, n=1; high-dose group: hypersensitivity and stridor, n=1; hypoxia, n=1; ventricular arrhythmia, n=1). Seventeen patients permanently discontinued STARTS-1 or -2 because of AEs; most were considered to be related to the disease under study. The 5 discontinuations due to AEs that were assessed as treatment related included decreased weight (n=1), convulsion (n=1), stridor (n=1), dyspnea and hypoxia (n=1), and macular rash (n=1).
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Discussion
In pediatric patients with PAH, treatment with high-dose sildenafil was associated with an increased risk of mortality compared with lower doses of sildenafil. A higher risk of death specifically was observed in patients with greater disease severity at baseline, in patients >20 kg, and in patients with IPAH/HPAH. The differences observed between treatment groups were unexpected because in the double-blind portion of this study, medium and high sildenafil doses were associated with improved exercise capacity, functional class, and hemodynamic parameters, whereas low-dose sildenafil appeared to be ineffective. 3 There were imbalances between treatment groups in baseline characteristics identified as predictive of mortality (Table   2 ). Adjustment for some of these factors influenced the hazard ratios comparing treatment groups (Table 6 ), but do not fully account for the increased mortality observed with high-dose sildenafil.
This study was unique for being a large, randomized, dose-ranging study of a single monotherapy in treatment-naïve patients. Overall, survival in all dose groups was favorable compared with other reports in children using PAH-specific drugs that were only approved for adult PAH. [4] [5] [6] [7] [8] [9] [10] Indeed, an alternate hypothesis is that there was little survival benefit with higher doses of sildenafil and that lower doses displayed an unexplained improvement in survival. Few 10 of the reported studies and registries included treatment-naïve patients. Some studies 7, 11 and all registries did not assess monotherapy (therapies could be added and/or changed), whereas 71% of STARTS patients were alive and receiving monotherapy for >3 years.
The observed survival in all dose groups was higher than 3-year survival rates for pediatric PAH patients before the availability of PAH-specific therapy [12] [13] [14] [15] and the median 10-month survival reported for the natural history of IPAH. 2). Adjustment for some of these factors influenced the hazard ratios comparing g t t tre ea at a me me m nt nt nt g g gro ro r up up Table 6 ), but do not fully account for the increased mortality observed with high-dose i ild ld den en enaf af afil il il.
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This study is inconsistent with results obtained using sildenafil monotherapy in adults with PAH (SUPER-1 study and SUPER-2 extension). Not unexpectedly, adult patients who received placebo in the 12-week SUPER-1 2 study had poorer long-term survival than patients treated with sildenafil in SUPER-1. 17 However, pediatric PAH patients who received placebo in the 16-week STARTS-1 study and subsequently received sildenafil had better long-term survival than children who began sildenafil in STARTS-1.
In the current study, RAP, PVRI, and etiology were found to be the combination of baseline factors with the highest prognostic potential in multivariate analysis when assessing survival from the start of STARTS-1; when assessing survival from the start of sildenafil, this was also one of the best combinations of variables. Hemodynamic parameters predicted pediatric PAH mortality in previous studies, specifically RAP (in IPAH patients 12, 18 and in children with mixed PAH etiology, some of whom received epoprostenol 19 ) and PVRI (in a large US registry, 9 in UK children, 11 and in univariate analysis of patients treated with bosentan 7 ) but it is unclear whether these factors were examined in other studies. 10, 20 Hemodynamic parameters, including RAP and PVR, similarly predict outcome in adult patients with PAH. 21, 22 Regarding univariate predictors of survival, similar to our study, WHO functional class is predictive of outcome in pediatric patients with IPAH, 11 in children with PAH treated with bosentan, 7 and in pediatric patients enrolled in PAH registries. 10, 20 No other pediatric study examining predictors of mortality assessed an exercise capacity endpoint, likely because of difficulties with performing such studies in pediatric patients. [23] [24] [25] Exercise capacity was prognostic in univariate analysis of STARTS-1/-2, despite being assessed in a limited subset of patients. Both functional class 26 and exercise capacity 27, 28 predict survival in adult patients with PAH, including those treated with sildenafil. 17, 29 Importantly, all analyses for this study assessed randomized, not received, sildenafil dose and therefore are insensitive to imbalances between groups in dose alterations during the study (Table 1) . Randomized doses are unbiased to confounding events that may occur during the parameters predicted pediatric PAH mortality in previous studies, specifically RAP (in IPAH patien ents ts ts , , an and d in in hildren with mixed PAH etiology, some of whom received epoprostenol 19 ) and PVRI (in a large ge U U US S S re re regi gi gist st stry ry ry, 9 9 9 i i in n n UK children, 11 and in univariate analysis of patients treated with bosentan f 7 ) but it is unclear whether these factors we ere re e e e exa xa xami mi mine ne ned d d i in o oth th t e er er studies. 10, 20 Hemodynamic param m me et eter r rs, including RAP P and d P P PV VR VR, similarly predict outcome n n n ad du dult patient nts s wi wi with th th P P PAH AH AH. , 21, 21 2 22 22 Rega ard rd rdin ng g uni iv va a ariate te e p p pre redi d ct ct tor ors s o of o su ur urv viva a al, , si simi mi mil la lar r to o o ou u ur s study y y, WH WH HO O O fu f n n nct t tion na a al cla as ss is pr pr pred ed edic ic icti ti tive ve ve o o of f f ou ou outc tc tcom om ome e e in in in p p ped ed edia ia iatr tr tric ic ic p p pat at atie ie ient nt nts s s wi wi with th th I I IPA PA PAH H, H, 11 11 i i in n n ch ch chil il ildr dr dren en en w w wit it ith h h PA PA PAH H H tr tr trea ea eate te ted d d wi wi with th th Table 2 ).
An explanation of the higher incidence of deaths observed after 2 years of STARTS-1/2 treatment in patients randomized to higher sildenafil doses remains elusive. Several observations suggest that other factors are influencing the survival comparisons. No deaths were considered by the investigator to be treatment related and the majority of the causes of death were known sequelae of PAH. Further, there was an inconsistency of the relationship between survival and exposure. Because sildenafil clearance was anticipated to increase with weight, dosing was doubled within each dose group for patients >45 vs 20-45 kg. However, pharmacokinetic modeling using samples obtained in STARTS-1 indicated that clearance plateaued at ~30 kg; therefore, patients >45 kg would achieve higher-than-anticipated exposure in medium-and highdose groups. Despite these higher exposures, 14% of patients >45 kg at baseline are known to have died versus 21% of patients 20-45 kg; no imbalance was evident across dose groups for patients >45 kg (Table 3) . Additionally, exposure-response analysis (data on file) showed that within the high-dose group, improved survival was associated with higher exposures.
Patients randomized to placebo in STARTS-1 (who then received sildenafil in STARTS-2) had better survival than patients receiving sildenafil throughout. As noted above, placebotreated patients in clinical studies of adults with PAH had poorer long-term survival than patients treated with sildenafil. 17 There is no plausible explanation why a 16-week delay in the start of Table 7 and Barst et al  3 ) ; across dose groups, sildenafil-treated STARTS-1 patients were clinically comparable, as were sildenafil dose groups in STARTS-2 (ie, including the re-randomized placebo-treated STARTS-1 patients). Adjustment for etiology, PVRI, and RAP, parameters identified as being prognostic for mortality, reduced hazard ratios comparing high and medium doses with placebo.
Taken together, these observations raise uncertainty concerning the strength of the relationship between sildenafil dose groups and survival.
The dose recommendations of the STARTS DMC were consistent with approved EMA dosing for pediatric sildenafil (patients 20 kg, 10 mg TID; >20 kg, 20 mg TID), which was based on population pharmacokinetics of STARTS-1 patients and known adult data, as well as efficacy data from STARTS-1. 3, 30 In this study, 5/55 (9%), 7/60 (12%), and 25/114 (22%)
patients died who were randomized to doses of sildenafil that were below, at, or above the EMA dosing instructions, respectively. An add dd dit it tio io ona na nal l 5 5 5 de d at at aths hs hs ( (on on on s s stu tu t dy dy dy t t tre re reat at atme me m nt nt n , , n= n= n 2; 2; ; a a aft ft fter er er d d dis is isco co ont nt ntin in inua ua uati ti tion on o , , , n= n= n 3) 3) 3) w w were date) for patients randomized to low-, medium-, and high-dose sildenafil, respectively, shows that deaths in the low-dose group remain below the other dose groups despite the prevalence of dose uptitrations in the low-dose group.
This study was limited by its essentially open-label nature after STARTS-1 was closed and unblinded. It is possible that uptitrations occurred after STARTS-1 data, which favored higher doses of sildenafil, were made public in 2009. Additionally, patients could have received commercial sildenafil and/or alternative PAH therapies after withdrawal; this information was not collected. Although no deaths were investigator-assessed as being related to sildenafil, such judgements are subjective; it is possible that sildenafil may cause harm in a way that is not easily apparent (for example, if sildenafil were to unexpectedly accelerate heart failure, the physician is likely to attribute death to underlying PAH). Additionally, it is unclear whether (or at which dose) sildenafil might be effective as part of combination therapy.
In summary, although children randomized to the high sildenafil dose group had an unexplained increased mortality compared with the lower sildenafil dose groups, multiple analyses raised uncertainty about the survival/dose relationship; all dose groups displayed favorable survival for children with PAH. STARTS-1 efficacy results 3 and the long-term survival rates favor use of lower sildenafil doses. After reviewing STARTS-2 survival data, it was recommended to downtitrate all patients remaining in the study to lower sildenafil doses, which are those approved in the European Union.
Acknowledgments: It is with sadness that the authors inform the reader that Dr Barst has passed away. We grieve the loss of a clinician so dedicated to improving the understanding and management of pulmonary arterial hypertension. Her contributions on behalf of pediatric patients were essential for the STARTS studies, and represent only a small portion of her work on behalf apparent (for example, if sildenafil were to unexpectedly accelerate heart failure e, , th th he e e ph ph phys ys ysic ic icia ia ian n is ikely to attribute death to underlying PAH). Additionally, it is unclear whether (or at which do ose se se) ) ) si si sild ld lden en enaf af a il m m mi ig ight be effective as part of com m mbi bi b n nation therapy y y. .
In sum mm ma ar ry y, al al a th h hou ough gh gh c chi hild ld ldr re ren n r ra andom om omize ed d t to th th the e h hi hig gh h s si i ild de dena nafi f f l do dose se se g gro roup up up h h had ad a a a an n A maximum of 2 uptitrations and 1 downtitration were allowed during the study. Doses received after dose titrations were equivalent to those in other dose groups (see Methods). *An additional 2 downtitrations occurred in patients who were treated with placebo in STARTS-1 but not randomized in STARTS-2. † Includes 1 patient who downtitrated in STARTS-1. ‡ Dummy uptitrations were used for patients who were already receiving the highest dose within their weight group (see Methods). § A change in weight to a new weight category resulted in a patient receiving the dose for the new weight category within that treatment group and was not regarded as a titration. bo e ne natriur t etic ic p pep pti ide; ; MA AP= P=me m an art r erial p pressure; ; PAP=p =pul ulmona n ry y a art r erial pr p essure; e; P PVR VR=p pul lmo m na nary ry v vascula l r resistan a ce; ; R RAP AP=rig ight h a atr tria i l pr pres e systemic vascular re resi sist tan ance ce; ; VO VO 2 2 2 =o oxyge gen up up ptake ke; ; WH WHO= O Wo W W rl r d d He Heal alth h O Org rgan a iz izat a io on. n. d on subset of p t atie ient nt ts s wh wh ho o we were re d dev evel e p opme mentally ly a abl ble e to to e exe xerc rcis ise e (n (n=1 =115 15 5). ). the last date they were known to be alive; if a patient received a transplant, they were censored the day before transplant (however, if the transplanted patient later died, the death was counted as an event). Patients at risk are those who are ongoing in the study or known to be alive at the specified time (ie, not dead, not lost to follow-up, or not on study long enough to reach time point).
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